<DOC>
	<DOCNO>NCT03003533</DOCNO>
	<brief_summary>This clinical research study conduct Spark Therapeutics , Inc. determine safety efficacy factor VIII gene transfer treatment SPK-8011 individual hemophilia A .</brief_summary>
	<brief_title>A Gene Transfer Study Hemophilia A</brief_title>
	<detailed_description>Hemophilia A condition blood unable clot effectively . It cause mutation deletion gene responsible produce blood-clotting factor VIII protein . Individuals hemophilia A suffer repeat bleed episode , often joint , cause chronic joint disease sometime result death due inability blood clot efficiently . This chronic joint disease significant physical , psychosocial , quality-of-life effect , include financial burden . The current treatment intravenous ( i.v . ) injection factor VIII protein product , either 2-3 time weekly response bleeding . Recent preliminary clinical data hemophilia B gene transfer study ( also conduct Spark Therapeutics ) show study participant achieve therapeutic factor IX activity level ( average maintain factor IX activity level around 30 % normal confirmed bleeds , receive Spark gene transfer , approach use novel bio-engineered recombinant adeno-associated viral ( rAAV ) vector carry high specific activity factor IX gene . The approach test clinical research study use modify novel AAV vector ( strong attraction human liver ) deliver human factor VIII ( hFVIII ) gene liver cell FVIII protein normally make .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males age18 year old Confirmed diagnosis hemophilia A evidenced medical history plasma FVIII activity level ≤ 2 % normal Have receive &gt; 150 exposure day ( EDs ) FVIII concentrate cryoprecipitate Have experience &gt; 10 bleed event previous 12 month receive ondemand therapy FVIII baseline level 12 % normal Have prior history allergic reaction FVIII product Have measurable inhibitor factor VIII inhibitor assess central laboratory prior history inhibitor FVIII protein Agree use reliable barrier contraception Evidence active hepatitis B C Currently antiviral therapy hepatitis B C Have significant underlying liver disease Have serological evidence* HIV1 HIV2 CD4 count ≤200/mm3 ( * participant HIV+ stable CD4 count &gt; 200/mm3 undetectable viral load eligible enroll ) Have detectable antibody reactive AAVSpark200 capsid Participated gene transfer trial within last 52 week clinical trial investigational product within last 12 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adeno-Associated Virus ( AAV )</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Blood Coagulation Disorders , Inherited</keyword>
	<keyword>Coagulation Protein Disorders</keyword>
	<keyword>Factor VIII ( FVIII )</keyword>
	<keyword>Factor VIII ( FVIII ) Deficiency</keyword>
	<keyword>Factor VIII ( FVIII ) Gene</keyword>
	<keyword>Factor VIII ( FVIII ) Protein</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Genetic Diseases , X-Linked</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Recombinant</keyword>
	<keyword>Vector</keyword>
</DOC>